| July 1, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| July 1, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| July 1, 2026 |
LLY |
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes |
Trial Milestone |
Phase 2 |
| July 1, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| July 1, 2026 |
BIIB |
Quarterly results filed (8-K) |
Earnings |
— |
| July 1, 2026 |
IBRX |
A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia |
Trial Milestone |
Phase 1 |
| July 1, 2026 |
VTRS |
8-K filed: Material agreement |
Corporate |
— |
| July 1, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| July 1, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| July 1, 2026 |
CLYM |
8-K filed: Leadership change |
Corporate |
— |
| July 1, 2026 |
AVLN |
8-K filed: Material agreement |
Corporate |
— |
| July 1, 2026 |
PVCT |
8-K filed: Leadership change |
Corporate |
— |
| July 1, 2026 |
CATX |
8-K filed: Other event |
Filing |
— |
| July 1, 2026 |
XFOR |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| July 1, 2026 |
ERAS |
A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors |
Trial Milestone |
Phase 1/Phase 2 |
| July 1, 2026 |
GOSS |
8-K filed: Reg FD disclosure |
Filing |
— |
| July 1, 2026 |
RIGL |
8-K filed: Leadership change |
Corporate |
— |
| July 2, 2026 |
AMGN |
A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations |
Trial Milestone |
Phase 1 |
| July 2, 2026 |
ARGX |
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. |
Trial Milestone |
Phase 2/Phase 3 |
| July 2, 2026 |
IOVA |
8-K filed: Other event |
Filing |
— |
| July 2, 2026 |
TENX |
8-K filed: Other event |
Filing |
— |
| July 2, 2026 |
ABVX |
6-K filed: Foreign issuer report |
Filing |
— |
| July 2, 2026 |
NGNE |
8-K filed: Material agreement, Other event |
Corporate |
— |
| July 2, 2026 |
RNXT |
8-K filed: Listing / standard notice |
Corporate |
— |
| July 2, 2026 |
NTHI |
8-K filed: Leadership change |
Corporate |
— |
| July 2, 2026 |
HALO |
8-K filed: Leadership change |
Corporate |
— |
| July 2, 2026 |
NGEN |
6-K filed: Foreign issuer report |
Filing |
— |
| July 2, 2026 |
CRMD |
8-K filed: Other event |
Filing |
— |
| July 2, 2026 |
CELZ |
8-K filed: Material agreement, Leadership change |
Corporate |
— |
| July 3, 2026 |
RCUS |
A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of Casdatifan in Healthy Adult Participants |
Trial Milestone |
Phase 1 |
| July 5, 2026 |
JAZZ |
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants |
Trial Milestone |
Phase 1 |
| July 6, 2026 |
LLY |
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes |
Trial Milestone |
Phase 2 |
| July 6, 2026 |
ABBV |
Quarterly results filed (8-K) |
Earnings |
— |
| July 6, 2026 |
REGN |
Quarterly results filed (8-K) |
Earnings |
— |
| July 6, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| July 6, 2026 |
INCY |
8-K filed: Other event |
Filing |
— |
| July 6, 2026 |
NUVB |
8-K filed: Other event |
Filing |
— |
| July 6, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| July 6, 2026 |
IMUX |
8-K filed: Leadership change |
Corporate |
— |
| July 6, 2026 |
IVVD |
8-K filed: Other event |
Filing |
— |
| July 6, 2026 |
CRBP |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| July 6, 2026 |
PBH |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| July 6, 2026 |
OMER |
8-K filed: Other event |
Filing |
— |
| July 6, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| July 6, 2026 |
AGEN |
8-K filed: Material agreement |
Corporate |
— |
| July 7, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| July 7, 2026 |
PRAX |
8-K filed: Other event |
Filing |
— |
| July 7, 2026 |
GRFS |
Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD) |
Trial Milestone |
Phase 3 |
| July 7, 2026 |
CMPS |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| July 7, 2026 |
MGTX |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| July 7, 2026 |
AWHL |
8-K/A filed: Leadership change |
Corporate |
— |
| July 7, 2026 |
VOR |
8-K filed: Leadership change |
Corporate |
— |
| July 7, 2026 |
VERA |
8-K filed: Other event |
Filing |
— |
| July 7, 2026 |
TTRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| July 7, 2026 |
ARDX |
4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs |
Trial Milestone |
Phase 2 |
| July 7, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| July 7, 2026 |
SMNR |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| July 7, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| July 7, 2026 |
VRTX |
8-K filed: Material agreement, Reg FD disclosure, Other event |
Corporate |
— |
| July 8, 2026 |
ABBV |
A Study to Evaluate the Safety and Effectiveness of JUVÉDERM Products in Adult Participants for the Change of Their Overall Facial Appearance |
Trial Milestone |
Phase 4 |
| July 8, 2026 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| July 8, 2026 |
MRNA |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| July 8, 2026 |
MIRM |
A Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of [14C]-MRM-3379 |
Trial Milestone |
Phase 1 |
| July 8, 2026 |
AMLX |
Avexitide for Treatment of Post-Bariatric Hypoglycemia |
Trial Milestone |
Phase 3 |
| July 8, 2026 |
AURA |
8-K filed: Leadership change |
Corporate |
— |
| July 8, 2026 |
BLRX |
6-K filed: Foreign issuer report |
Filing |
— |
| July 8, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| July 8, 2026 |
APLM |
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors |
Trial Milestone |
Phase 1 |
| July 9, 2026 |
AZN |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| July 9, 2026 |
BMY |
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma |
Trial Milestone |
Phase 3 |
| July 9, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| July 9, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| July 9, 2026 |
REGN |
A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD) |
Trial Milestone |
Phase 3 |
| July 9, 2026 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| July 9, 2026 |
IONS |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| July 9, 2026 |
TVTX |
8-K filed: Leadership change |
Corporate |
— |
| July 9, 2026 |
NRIX |
Quarterly results filed (8-K) |
Earnings |
— |
| July 9, 2026 |
VERA |
8-K filed: Leadership change |
Corporate |
— |
| July 9, 2026 |
KYTX |
8-K filed: Material agreement |
Corporate |
— |
| July 9, 2026 |
TRAW |
8-K filed: Leadership change |
Corporate |
— |
| July 9, 2026 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| July 9, 2026 |
SXTP |
8-K filed: Other event |
Filing |
— |
| July 10, 2026 |
GSK |
Results filed (6-K) |
Earnings |
— |
| July 10, 2026 |
BNTX |
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children |
Trial Milestone |
Phase 3 |
| July 10, 2026 |
IONS |
8-K filed: Reg FD disclosure |
Filing |
— |
| July 10, 2026 |
RARE |
Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS) |
Trial Milestone |
Phase 3 |
| July 10, 2026 |
ANVS |
8-K filed: Other event |
Filing |
— |
| July 10, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| July 10, 2026 |
CLRB |
8-K filed: Leadership change |
Corporate |
— |
| July 10, 2026 |
TRAW |
8-K filed: Other event |
Filing |
— |
| July 10, 2026 |
CERS |
8-K filed: Leadership change |
Corporate |
— |
| July 13, 2026 |
LLY |
A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function |
Trial Milestone |
Phase 1 |
| July 13, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| July 13, 2026 |
GSK |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| July 13, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| July 13, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| July 13, 2026 |
BMRN |
8-K/A filed: Other event |
Filing |
— |
| July 13, 2026 |
EYPT |
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 |
Trial Milestone |
Phase 3 |
| July 13, 2026 |
OCGN |
8-K filed: Other event |
Filing |
— |
| July 13, 2026 |
EWTX |
8-K filed: Acquisition completed, Reg FD disclosure |
Corporate |
— |
| July 13, 2026 |
MBX |
8-K filed: Leadership change |
Corporate |
— |
| July 13, 2026 |
ANRO |
Quarterly results filed (8-K) |
Earnings |
— |
| July 13, 2026 |
ONCY |
8-K filed: Other event |
Filing |
— |
| July 13, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| July 13, 2026 |
ERAS |
8-K filed: Other event |
Filing |
— |
| July 13, 2026 |
AGEN |
8-K filed: Material agreement, Reg FD disclosure, Other event |
Corporate |
— |
| July 13, 2026 |
QTTB |
8-K filed: Other event |
Filing |
— |
| July 13, 2026 |
QTTB |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| July 14, 2026 |
AZN |
6-K filed: Corporate announcement |
Corporate |
— |
| July 14, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| July 14, 2026 |
ABBV |
ELAPR002f Injectable Gel in the Treatment of Atrophic Acne Scars |
Trial Milestone |
Phase 3 |
| July 14, 2026 |
TAK |
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis |
Trial Milestone |
Phase 2 |
| July 14, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| July 14, 2026 |
PVLA |
8-K filed: Other event |
Filing |
— |
| July 14, 2026 |
IMUX |
8-K filed: Reg FD disclosure |
Filing |
— |
| July 14, 2026 |
IKT |
8-K filed: Other event |
Filing |
— |
| July 14, 2026 |
SNDX |
8-K filed: Other event |
Filing |
— |
| July 14, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| July 14, 2026 |
OTLC |
8-K filed: Other event |
Filing |
— |
| July 14, 2026 |
OTLC |
8-K filed: Leadership change |
Corporate |
— |
| July 14, 2026 |
CAPR |
8-K filed: Material agreement |
Corporate |
— |
| July 14, 2026 |
ANRO |
8-K filed: Material agreement |
Corporate |
— |
| July 14, 2026 |
ANGO |
Quarterly results filed (8-K) |
Earnings |
— |
| July 14, 2026 |
ERAS |
8-K filed: Other event |
Filing |
— |
| July 14, 2026 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| July 14, 2026 |
WST |
8-K filed: Material agreement |
Corporate |
— |
| July 14, 2026 |
APLM |
6-K filed: Foreign issuer report |
Filing |
— |
| July 14, 2026 |
GNPX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| July 15, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| July 15, 2026 |
JNJ |
Quarterly results filed (8-K) |
Earnings |
— |
| July 15, 2026 |
ABBV |
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine |
Trial Milestone |
Phase 2 |
| July 15, 2026 |
SVA |
6-K filed: Foreign issuer report |
Filing |
— |
| July 15, 2026 |
JAZZ |
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms |
Trial Milestone |
Phase 1 |
| July 15, 2026 |
JAZZ |
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers |
Trial Milestone |
Phase 3 |
| July 15, 2026 |
AXSM |
8-K filed: Other event |
Filing |
— |
| July 15, 2026 |
DFTX |
A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage) |
Trial Milestone |
Phase 3 |
| July 15, 2026 |
CLDX |
8-K filed: Leadership change |
Corporate |
— |
| July 15, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| July 15, 2026 |
MANE |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| July 15, 2026 |
IOVA |
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants |
Trial Milestone |
Phase 1 |
| July 15, 2026 |
PCVX |
8-K filed: Leadership change |
Corporate |
— |
| July 15, 2026 |
MLTX |
8-K filed: Other event |
Filing |
— |
| July 15, 2026 |
CANF |
Namodenoson Treatment of Advanced Pancreatic Cancer |
Trial Milestone |
Phase 2 |
| July 15, 2026 |
AWHL |
8-K filed: Material agreement |
Corporate |
— |
| July 15, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| July 15, 2026 |
PBH |
First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer |
Trial Milestone |
Phase 1/Phase 2 |
| July 15, 2026 |
PBH |
8-K filed: Material agreement |
Corporate |
— |
| July 15, 2026 |
CLYM |
A Phase 1 Study of CLYM116 in Normal Healthy Volunteers |
Trial Milestone |
Phase 1 |
| July 15, 2026 |
NTHI |
8-K filed: Reg FD disclosure |
Filing |
— |
| July 15, 2026 |
ALDX |
8-K filed: Other event |
Filing |
— |
| July 15, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| July 15, 2026 |
ENSC |
8-K filed: Leadership change |
Corporate |
— |
| July 15, 2026 |
GOSS |
8-K filed: Leadership change |
Corporate |
— |
| July 15, 2026 |
QTTB |
8-K filed: Material agreement |
Corporate |
— |
| July 16, 2026 |
PFE |
A Study to Learn How a Single Dose of the Study Medicine Called PF-08057418 is Tolerated in the Body of Healthy Adults. |
Trial Milestone |
Phase 1 |
| July 16, 2026 |
BMY |
A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy |
Trial Milestone |
Phase 4 |
| July 16, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| July 16, 2026 |
INSM |
8-K filed: Reg FD disclosure |
Filing |
— |
| July 16, 2026 |
IMVT |
An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
Trial Milestone |
Phase 2 |
| July 17, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| July 17, 2026 |
GSK |
Results filed (6-K) |
Earnings |
— |
| July 17, 2026 |
ABBV |
Study to Assess Adverse Events and How Oral Emraclidine Moves Through the Body of Adult Healthy Volunteers |
Trial Milestone |
Phase 1 |
| July 17, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| July 17, 2026 |
KPTI |
8-K filed: Leadership change |
Corporate |
— |
| July 17, 2026 |
EYPT |
8-K filed: Material agreement |
Corporate |
— |
| July 17, 2026 |
OGN |
8-K filed: Other event |
Filing |
— |
| July 17, 2026 |
ACTU |
8-K filed: Listing / standard notice |
Corporate |
— |
| July 20, 2026 |
GSK |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| July 20, 2026 |
NVO |
A Study on How NNC0174-1213 Works in People With Overweight or Obesity. |
Trial Milestone |
Phase 1 |
| July 20, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| July 20, 2026 |
FDMT |
8-K filed: Other event |
Filing |
— |
| July 20, 2026 |
IMVT |
To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP |
Trial Milestone |
Phase 2 |
| July 20, 2026 |
RGNX |
8-K filed: Other event |
Filing |
— |
| July 20, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| July 20, 2026 |
DYN |
8-K filed: Other event |
Filing |
— |
| July 20, 2026 |
ONCY |
8-K filed: Other event |
Filing |
— |
| July 20, 2026 |
OMER |
8-K filed: Other event |
Filing |
— |
| July 20, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| July 20, 2026 |
OKYO |
Results filed (20-F) |
Earnings |
— |
| July 20, 2026 |
SXTP |
8-K filed: Reg FD disclosure |
Filing |
— |
| July 21, 2026 |
NVS |
6-K filed: Foreign issuer report |
Filing |
— |
| July 21, 2026 |
LLY |
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight |
Trial Milestone |
Phase 3 |
| July 21, 2026 |
ABBV |
A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults. |
Trial Milestone |
Phase 1 |
| July 21, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| July 21, 2026 |
INBS |
8-K filed: Reg FD disclosure |
Filing |
— |
| July 21, 2026 |
RCUS |
A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies |
Trial Milestone |
Phase 1 |
| July 21, 2026 |
KRYS |
8-K filed: Other event |
Filing |
— |
| July 21, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| July 21, 2026 |
SGMT |
8-K filed: Reg FD disclosure |
Filing |
— |
| July 21, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| July 21, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| July 21, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| July 21, 2026 |
ALZN |
8-K filed: Other event |
Filing |
— |
| July 21, 2026 |
APLM |
6-K filed: Foreign issuer report |
Filing |
— |
| July 22, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| July 22, 2026 |
SMMT |
8-K filed: Other event |
Filing |
— |
| July 22, 2026 |
SUPN |
Quarterly results filed (8-K) |
Earnings |
— |
| July 22, 2026 |
DYN |
8-K filed: Material agreement, Other event |
Corporate |
— |
| July 22, 2026 |
LBRX |
8-K filed: Other event |
Filing |
— |
| July 22, 2026 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| July 22, 2026 |
CRVS |
8-K filed: Leadership change |
Corporate |
— |
| July 22, 2026 |
VALN |
6-K filed: Foreign issuer report |
Filing |
— |
| July 22, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| July 22, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| July 22, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| July 22, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| July 22, 2026 |
TPST |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| July 23, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| July 23, 2026 |
AMGN |
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity |
Trial Milestone |
Phase 3 |
| July 23, 2026 |
ARGX |
6-K filed: Foreign issuer report |
Filing |
— |
| July 23, 2026 |
INBS |
8-K filed: Reg FD disclosure |
Filing |
— |
| July 23, 2026 |
SMMT |
8-K filed: Material agreement |
Corporate |
— |
| July 23, 2026 |
SMMT |
Quarterly results filed (8-K) |
Earnings |
— |
| July 23, 2026 |
IKT |
8-K filed: Reg FD disclosure |
Filing |
— |
| July 23, 2026 |
NVCR |
Quarterly results filed (8-K) |
Earnings |
— |
| July 23, 2026 |
UTHR |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| July 23, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| July 23, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| July 23, 2026 |
FTH |
8-K filed: Leadership change |
Corporate |
— |
| July 23, 2026 |
WST |
Quarterly results filed (8-K) |
Earnings |
— |
| July 24, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| July 24, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| July 24, 2026 |
BNTX |
A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19 |
Trial Milestone |
Phase 3 |
| July 24, 2026 |
MRNA |
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults |
Trial Milestone |
Phase 3 |
| July 24, 2026 |
VIR |
8-K filed: Leadership change |
Corporate |
— |
| July 24, 2026 |
IVVD |
8-K filed: Listing / standard notice |
Corporate |
— |
| July 24, 2026 |
ONCY |
8-K filed: Listing / standard notice |
Corporate |
— |
| July 24, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| July 24, 2026 |
OTLK |
8-K filed: Other event |
Filing |
— |
| July 24, 2026 |
OTLK |
8-K filed: Leadership change |
Corporate |
— |
| July 24, 2026 |
MNKD |
8-K filed: Other event |
Filing |
— |
| July 27, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| July 27, 2026 |
AZN |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| July 27, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| July 27, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| July 27, 2026 |
REGN |
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery |
Trial Milestone |
Phase 3 |
| July 27, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| July 27, 2026 |
GILD |
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103) |
Trial Milestone |
Phase 2 |
| July 27, 2026 |
ARGX |
6-K filed: Foreign issuer report |
Filing |
— |
| July 27, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| July 27, 2026 |
SRPT |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| July 27, 2026 |
SLS |
Quarterly results filed (8-K) |
Earnings |
— |
| July 27, 2026 |
KYTX |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| July 27, 2026 |
MPLT |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| July 27, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| July 27, 2026 |
KYMR |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| July 27, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| July 27, 2026 |
GOSS |
Quarterly results filed (8-K) |
Earnings |
— |
| July 27, 2026 |
SPRB |
8-K filed: Leadership change |
Corporate |
— |
| July 28, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| July 28, 2026 |
GSK |
Results filed (6-K) |
Earnings |
— |
| July 28, 2026 |
GSK |
Results filed (6-K) |
Earnings |
— |
| July 28, 2026 |
JNJ |
8-K filed: Reg FD disclosure |
Filing |
— |
| July 28, 2026 |
INCY |
Quarterly results filed (8-K) |
Earnings |
— |
| July 28, 2026 |
ALKS |
Quarterly results filed (8-K) |
Earnings |
— |
| July 28, 2026 |
DNLI |
8-K filed: Acquisition completed |
Corporate |
— |
| July 28, 2026 |
GRCE |
8-K filed: Other event |
Filing |
— |
| July 28, 2026 |
RLMD |
8-K filed: Reg FD disclosure |
Filing |
— |
| July 28, 2026 |
BCAX |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| July 28, 2026 |
ALT |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| July 28, 2026 |
KNSA |
Quarterly results filed (8-K) |
Earnings |
— |
| July 28, 2026 |
SYRE |
A Study of SPY002-072 in Healthy Volunteers |
Trial Milestone |
Phase 1 |
| July 28, 2026 |
TTRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| July 28, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| July 28, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| July 28, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| July 28, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| July 28, 2026 |
TPST |
8-K filed: Other event |
Filing |
— |
| July 28, 2026 |
LTRN |
Study of LP-184 in Patients With Advanced Solid Tumors |
Trial Milestone |
Phase 1/Phase 2 |
| July 29, 2026 |
JNJ |
8-K filed: Reg FD disclosure |
Filing |
— |
| July 29, 2026 |
INCY |
A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors |
Trial Milestone |
Phase 1/Phase 2 |
| July 29, 2026 |
BIIB |
Quarterly results filed (8-K) |
Earnings |
— |
| July 29, 2026 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| July 29, 2026 |
IONS |
Quarterly results filed (8-K) |
Earnings |
— |
| July 29, 2026 |
GRFS |
6-K filed: Foreign issuer report |
Filing |
— |
| July 29, 2026 |
TEVA |
Quarterly results filed (8-K) |
Earnings |
— |
| July 29, 2026 |
BSX |
Quarterly results filed (8-K) |
Earnings |
— |
| July 29, 2026 |
CORT |
Quarterly results filed (8-K) |
Earnings |
— |
| July 29, 2026 |
DYN |
Quarterly results filed (8-K) |
Earnings |
— |
| July 29, 2026 |
GKOS |
Quarterly results filed (8-K) |
Earnings |
— |
| July 29, 2026 |
LBRX |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| July 29, 2026 |
PTGX |
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PN-881 in Healthy Subjects. |
Trial Milestone |
Phase 1 |
| July 29, 2026 |
QURE |
Quarterly results filed (8-K) |
Earnings |
— |
| July 29, 2026 |
CAPR |
8-K filed: Other event |
Filing |
— |
| July 29, 2026 |
KURA |
8-K filed: Leadership change |
Corporate |
— |
| July 29, 2026 |
XNCR |
Quarterly results filed (8-K) |
Earnings |
— |
| July 30, 2026 |
NVS |
Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants |
Trial Milestone |
Phase 1 |
| July 30, 2026 |
BMY |
Quarterly results filed (8-K) |
Earnings |
— |
| July 30, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| July 30, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| July 30, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| July 30, 2026 |
REGN |
Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults |
Trial Milestone |
Phase 1 |
| July 30, 2026 |
REGN |
Quarterly results filed (8-K) |
Earnings |
— |
| July 30, 2026 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| July 30, 2026 |
BIIB |
A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD) |
Trial Milestone |
Phase 3 |
| July 30, 2026 |
BNTX |
Results filed (20-F/A) |
Earnings |
— |
| July 30, 2026 |
NBIX |
Quarterly results filed (8-K) |
Earnings |
— |
| July 30, 2026 |
AGIO |
Quarterly results filed (8-K) |
Earnings |
— |
| July 30, 2026 |
IBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| July 30, 2026 |
ALNY |
Quarterly results filed (8-K) |
Earnings |
— |
| July 30, 2026 |
EYPT |
8-K filed: Other event |
Filing |
— |
| July 30, 2026 |
GRFS |
6-K filed: Foreign issuer report |
Filing |
— |
| July 30, 2026 |
MDGL |
Quarterly results filed (8-K) |
Earnings |
— |
| July 30, 2026 |
PHAR |
6-K filed: Foreign issuer report |
Filing |
— |
| July 30, 2026 |
REPL |
8-K filed: Reg FD disclosure |
Filing |
— |
| July 30, 2026 |
ANNX |
8-K filed: Material agreement, Other event |
Corporate |
— |
| July 30, 2026 |
BCYC |
Quarterly results filed (8-K) |
Earnings |
— |
| July 30, 2026 |
VCEL |
Quarterly results filed (8-K) |
Earnings |
— |
| July 30, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| July 30, 2026 |
PHAT |
Quarterly results filed (8-K) |
Earnings |
— |
| July 30, 2026 |
ORIC |
8-K filed: Leadership change |
Corporate |
— |
| July 30, 2026 |
CAPR |
8-K filed: Other event |
Filing |
— |
| July 30, 2026 |
ALT |
RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight |
Trial Milestone |
Phase 2 |
| July 30, 2026 |
WVE |
Quarterly results filed (8-K) |
Earnings |
— |
| July 30, 2026 |
ALDX |
8-K filed: Material agreement |
Corporate |
— |
| July 30, 2026 |
BCLI |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| July 30, 2026 |
IRON |
Quarterly results filed (8-K) |
Earnings |
— |
| July 30, 2026 |
AMRX |
Quarterly results filed (8-K) |
Earnings |
— |
| July 30, 2026 |
CLLS |
6-K filed: Foreign issuer report |
Filing |
— |
| July 30, 2026 |
CERS |
Quarterly results filed (8-K) |
Earnings |
— |
| July 30, 2026 |
CRIS |
8-K filed: Listing / standard notice |
Corporate |
— |
| July 30, 2026 |
GNPX |
8-K filed: Listing / standard notice, Other event |
Corporate |
— |
| July 30, 2026 est. |
ILMN |
Q2 2026 Earnings |
Earnings |
— |
| July 30, 2026 |
ILMN |
Open-Label Study of 18F-mFBG for Imaging Neuroblastoma |
Trial Milestone |
Phase 3 |
| July 30, 2026 |
ILMN |
Quarterly results filed (8-K) |
Earnings |
— |
| July 31, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| July 31, 2026 |
ABBV |
Quarterly results filed (8-K) |
Earnings |
— |
| July 31, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| July 31, 2026 |
BNTX |
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age |
Trial Milestone |
Phase 3 |
| July 31, 2026 |
MRNA |
Q2 2026 Earnings + Norovirus Interim Analysis |
Earnings |
Phase 3 interim |
| July 31, 2026 |
MRNA |
Quarterly results filed (8-K) |
Earnings |
— |
| July 31, 2026 |
KPTI |
8-K filed: Other event |
Filing |
— |
| July 31, 2026 |
ADRX |
Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension |
Trial Milestone |
Phase 1 |
| July 31, 2026 |
OCGN |
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME) |
Trial Milestone |
Phase 1 |
| July 31, 2026 |
REPL |
8-K filed: Other event |
Filing |
— |
| July 31, 2026 |
BCYC |
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression |
Trial Milestone |
Phase 1/Phase 2 |
| July 31, 2026 |
VTGN |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| July 31, 2026 |
HUMA |
8-K filed: Listing / standard notice |
Corporate |
— |
| July 31, 2026 |
TENX |
Quarterly results filed (8-K) |
Earnings |
— |
| July 31, 2026 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| July 31, 2026 |
TRAW |
8-K filed: Listing / standard notice |
Corporate |
— |
| July 31, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| July 31, 2026 |
OGN |
8-K filed: Reg FD disclosure |
Filing |
— |
| July 31, 2026 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |